托尔瓦普坦对ADPKD的进展和全身炎症的影响
Ahmet Ziya Şahin1, Orhan Özdemir2
1Department of Nephrology, Adana City Research and Training Hospital, Adana, Turkey. drahmetziya@hotmail.com.
在自身主导性多囊病 (ADPKD) 患者中,托尔瓦普坦可降低炎症并保持功能. 在接受托尔瓦普坦治疗的患者中,该研究观察到炎症标志物降低和稳定的膜过率 (GFR).
科学领域:
- 肝脏病学
- 炎症研究
- 药理学
背景情况:
- 炎症是自体主导多囊病 (ADPKD) 进展的一个关键因素.
- 托尔瓦普坦是一种血管压素V2受体对抗剂,具有潜在的抗炎性质,需要在ADPKD中进行研究.
研究的目的:
- 评估tolvaptan对ADPKD患者的炎症标志物和功能的影响.
- 评估托尔瓦普坦对全身炎症和病进展的影响.
主要方法:
- 两中心的回顾性队列研究,涉及80名ADPKD患者 (40名托尔瓦,40名对照).
- 在1年的随访期间分析炎症标志物 (CRP,SII,PLR,NLR) 和脏参数 (GFR,蛋白尿).
- 托尔瓦普坦和对照组之间的标记变化的比较.
主要成果:
- 托尔瓦普坦组的C反应蛋白 (CRP),全身炎症指数 (SII),血小板与淋巴细胞的比率 (PLR),蛋白尿和尿酸显著降低.
- 对照组显示这些炎症标志物增加.
- 托尔瓦普坦组的淋巴细胞过率 (GFR) 保持稳定,与对照组的显著下降形成鲜明对比.
结论:
- 在ADPKD患者中,托尔瓦普坦可能具有有益的抗炎作用.
- 托尔瓦普坦治疗似乎可以保持ADPKD的功能.
- 这些发现支持减少全身炎症和ADPKD中改善的结局之间的联系.
更多相关视频
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
08:46Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
Published on: September 1, 2015
相关概念视频
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury II: Pathophysiology
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury III: Clinical Manifestations
Heart Failure Drugs: Diuretics
Renal Drug Excretion: Tubular Secretion
